A Phase 2 interventional study of GFT505 80mg and Placebo in Atherogenic Dyslipidaemia and Abdominal Obesity, sponsored by Genfit. Completed at 47 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-07.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Obesity, Abdominal with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Obesity, Abdominal · France.
Among the 15 studies in Obesity, Abdominal with a site in France, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 2nd registered.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
Browse Obesity, Abdominal studies →3 of the 15 studies in Obesity, Abdominal with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45 · Women only
University Hospital, Rouen · Sites in France
Ages 18–65
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Median enrollment 53 across the 13 interventional studies, 608 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 3 studies filed under Obesity, Abdominal — fewer than ten, so there is no comparison to draw.
1 of the studies in Obesity, Abdominal with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04942093University Hospital, RouenNUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Obesity, Abdominal with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of GFT505 80mg in reducing serum Triglycerides (TG) and increasing High Density Lipoprotein Cholesterol (HDL-C) levels compared with placebo in atherogenic dyslipidaemic patients with abdominal obesity, and to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 during 28 days.
The study period per patient is 7 to 14 weeks: a screening period (1 to 8 weeks) will precede a 4-week double-blind treatment period and a 2-week follow-up period.
During the screening period, patients will be asked to start or continue adequate diet and exercise and to stop their lipid-lowering medication (for not treatment-naïve patients). For patient taking any lipid-regulating medication, a minimum of 8-week wash-out from lipid-regulating therapies (fibrates, statins, …) is required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GFT505 80mg
Drug: Placebo
hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Decrease in serum Triglycerides (TG) level
To evaluate the efficacy of GFT505 80mg in reducing serum TG compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)
Time frame: 28 days
Increase in serum High Density Lipoprotein Cholesterol (HDL-C) level
To evaluate the efficacy of GFT505 80mg in increasing HDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)
Time frame: 28 days
Decrease in Low Density Lipoprotein Cholesterol (LDL-C) levels
To evaluate the efficacy of GFT505 80mg in reducing LDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)
Time frame: 28 days
Decrease in non-HDL-C (High Density Lipoprotein Cholesterol) levels
To evaluate the efficacy of GFT505 80mg in reducing non-HDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)
Time frame: 28 days
The record gives a start of Jan 2009, a primary completion of Sep 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor